![Mohamed Asiri Profile](https://pbs.twimg.com/profile_images/1764607552224944128/UffK_8hA_x96.jpg)
Mohamed Asiri
@MohAsiri00
Followers
212
Following
2K
Statuses
174
Intern | King Saud Bin Abdulaziz University Alumnus
Joined August 2023
RT @AaronGoodman33: Cilta-cel integrated into TP53 causing a T-cell lymphoma. CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor I…
0
16
0
@AbduIIahAltasan Not a surprise, the best pediatrician any place would be lucky to have you 💪💪
0
0
1
RT @BayounisM: Honored to have attended and presented at #SSORL2025—an unforgettable experience filled with learning, insights, and great d…
0
7
0
RT @Moh_A_Almanna: Amazing first day! Thankful for everyone who came by today. Make sure to visit us at the Neuroan Atlas booth tomorrow at…
0
1
0
@Oalmajhdi Actual average CTU experience is adjusting sliding scale and lasix dose right up to discharge and calling ID for about 10 times a day
1
0
2
Chemo-free regimens!
📢 Exciting results from MDACC! 📊 Blinatumomab + Ponatinib (Ph+ ALL): ✔️ 3-year EFS: 77% ✔️ 3-year OS: 91% ✔️ CMR: 83% | NGS-neg: 97% 👥 n=60 | Median age: 55 🩺 CV risks: HTN 45%, DM 22%, HL 32%, CAD 2% 🧬 WBC >75: 38% relapse risk 🌟 Abstract #ASH2024 #LeukemiaResearch #ALL
0
0
7
RT @ziyadalhajeri: Honored to present our abstract in the 8th Saudi Society of Nephrology and Trasnplantation Congress and engage with lead…
0
4
0
@AAlomayyer @enayah_5056 @NGHAnews @sanggovsa الله يرفع قدركم ويكتب أجركم ويجعلها في ميزان حسناتكم. Proud of yall ❤️
1
0
1
RT @NEJM: The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free surviv…
0
336
0
RT @rajshekharucms: With #ASH24 around the corner, here are my picks on clinically relevant abstracts in #MultipleMyeloma, AL #Amyloidosis,…
0
26
0
RT @AaronGoodman33: One of the best reviews I have read in a long time. T cell lymphomas are so interesting and complex. Hopefully better…
0
62
0